328 results on '"Durey, Marie-Agnès"'
Search Results
2. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
3. Clinical Relevance of Anti-C3 and Anti-C4 Autoantibodies in Lupus Nephritis
4. Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma
5. C3 Glomerulopathy With Concurrent Thrombotic Microangiopathy: Clinical and Immunological Features
6. Genetic Diagnosis Guides Treatment of Autoimmune Enteropathy
7. List of contributors
8. Innate immune responses in COVID-19
9. Systematic review of atypical hemolytic uremic syndrome biomarkers
10. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series
11. The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
12. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers
13. Precision of autoantibody assays in clinical diagnostic laboratories: What is the reality?
14. Complément dans les glomérulopathies à dépôts de C3 : exploration et conséquences thérapeutiques
15. Impact des autoanticorps préexistants asymptomatiques sur la survenue des toxicités immuno-induites.
16. Analytical validation of an alternative method to quantify specific antibodies in 3 applications
17. Hemolytic Tests Exploring Factor H Functional Activities
18. Sheep Erythrocyte Preparation for Hemolytic Tests Exploring Complement Functional Activities
19. Pernicious anemia with false normal vitamin B12 levels caused by intrinsic factor antibodies interference: a case report
20. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies
21. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy
22. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
23. A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions
24. Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report
25. Advice in autoimmunity biological diagnosis: guidelines for drafting comments on biological results
26. Auto-immunité et gestion des toxicités des traitements par anti-check point inhibiteurs
27. Autoantibodies against complement proteins in patients with antiphospholipid syndrome: Prevalence and clinical associations.
28. Supplementary Tables from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
29. Supplementary Figures from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
30. Data from Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
31. Data from Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
32. Supplementary Tables from Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
33. Supplementary Figures from Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
34. Supplementary Table 1 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
35. Supplementary Figure 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
36. Supplementary Figure 1 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
37. Supplementary Table 5 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
38. Supplementary Table 4 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
39. Supplementary Table 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
40. Supplementary Figure 3 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
41. Supplementary Table 3 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
42. Data not shown from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
43. Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis
44. Atypical aHUS: State of the art
45. 39 Humoral complementomics – Exploration of non-invasive complement biomarkers as predictors of renal cancer progression
46. Hyperoxidized Species of Heme Have a Potent Capacity to Induce Autoreactivity of Human IgG Antibodies
47. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
48. Chapitre 22 - Les mécanismes physiopathologiques de l'auto-immunité
49. Chapitre 6 - Le système du complément
50. Chapter 3 - Innate immune responses in COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.